Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study
Chao Liu,Yu-Ping Zhou,Tian-Yu Lian,Ruo-Nan Li,Jing-Si Ma,Yin-Jian Yang,Si-Jin Zhang,Xian-Mei Li,Lu-Hong Qiu,Bao-Chen Qiu,Li-Yan Ren,Jia Wang,Zhi-Yan Han,Jing-Hui Li,Lan Wang,Xi-Qi Xu,Kai Sun,Lian-Feng Chen,Chun-Yan Cheng,Ze-Jian Zhang,Zhi-Cheng Jing,Chao LiuYu-Ping ZhouTian-Yu LianRuo-Nan LiJing-Si MaYin-Jian YangSi-Jin ZhangXian-Mei LiLu-Hong QiuBao-Chen QiuLi-Yan RenJia WangZhi-Yan HanJing-Hui LiLan WangXi-Qi XuKai SunLian-Feng ChenChun-Yan ChengZe-Jian ZhangZhi-Cheng JingDepartment of Cardiology,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China. (C.L.,Y.-P.Z.,X.-M.L.,L.-H.Q.,B.-C.Q.,L.-Y.R.,X.-Q.X.,L.-F.C.)State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China. (Y.-J.Y.,K.S.,Z.-J.Z.)State Key Laboratory of Cardiovascular Disease,FuWai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China. (Z.-Y.H.,J.-H.L.)Department of Cardiology,Guangdong Cardiovascular Institute,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou,China (T.-Y.L.,S.-J.Z.,C.-Y.C.,Z.-C.J).School of Pharmacy,Henan University,Zhengzhou,China (R.-N.L.,J.-S.M.).Department of Medical Laboratory,Weifang Medical University,China (J.W.).Department of Cardio-Pulmonary Circulation,Shanghai Pulmonary Hospital,Tongji University,China (L.W.).
DOI: https://doi.org/10.1161/hypertensionaha.123.22274
IF: 9.8968
2023-12-21
Hypertension
Abstract:Hypertension, Ahead of Print. BACKGROUND:The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is multifactorial and growing evidence has indicated that hematological disorders are involved. Clonal hematopoiesis of indeterminate potential (CHIP) has recently been associated with an increased risk of both hematological malignancies and cardiovascular diseases. However, the prevalence and clinical relevance of CHIP in patients with CTEPH remains unclear.METHODS:Using stepwise calling on next-generation sequencing data from 499 patients with CTEPH referred to 3 centers between October 2006 and December 2021, CHIP mutations were identified. We associated CHIP with all-cause mortality in patients with CTEPH. To provide insights into potential mechanisms, the associations between CHIP and inflammatory markers were also determined.RESULTS:In total, 47 (9.4%) patients with CTEPH carried at least 1 CHIP mutation at a variant allele frequency of ≥2%. The most common mutations were inDNMT3A,TET2,RUNX1, andASXL1. During follow-up (mean, 55 months), deaths occurred in 22 (46.8%) and 104 (23.0%) patients in the CHIP and non-CHIP groups, respectively (P<0.001, log-rank test). The association of CHIP with mortality remained robust in the fully adjusted model (hazard ratio, 2.190 [95% CI, 1.257–3.816];P=0.006). Moreover, patients with CHIP mutations showed higher circulating interleukin-1β and interleukin-6 and lower interleukin-4 and IgG galactosylation levels.CONCLUSIONS:This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.
peripheral vascular disease